Email Updates

Search form

You are here

Webinar & Meeting Reports

  • May 18, 2013

    AVAC is excited to be working with civil society and research partners across the globe on a number of community events to commemorate HIV Vaccine Awareness Day.

  • May 9, 2013

    The fourth webinar in our series addressed a range of topics in HIV prevention research, hosted jointly by NAM and AVAC, and looked at the current situation regarding pre-exposure prophylaxis (PrEP) in Europe and the US. Presenters discussed the ongoing IPERGAY study in France and the PROUD study in England, and reviewed progress in the NEXT-PrEP and demonstration studies in the US.

  • April 30, 2013

    The US National Institute of Allergy and Infectious Diseases (NIAID) and HIV Vaccine Trials Network (HVTN) accounced that the HVTN 505 AIDS vaccine clinical trial would cease immunizations early after the independent Data and Safety Monitoring Board (DSMB) determined during a scheduled interim review that the vaccine regimen being tested is not effective.

  • April 8, 2013

    Jeanne Marrazzo (VOICE protocol co-chair) and Ian McGowan (co-principal investigator of the Microbicide Trials Network) discussed the VOICE results and what they mean for the rectal microbicide field moving forward. This call was presented through a collaboration between IRMA and AVAC.

  • April 2, 2013

    In the wake of exciting new data presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta, AVAC hosted a webinar to review the current status on research towards an HIV/AIDS cure. The webinar featured Steven Deeks, MD, a researcher at the University of California, San Francisco, who discussed the latest research and what to look forward to in coming years, followed by a Q&A.

  • March 28, 2013

    This was the third webinar in our series addressing a range of topics in HIV prevention research, hosted jointly by NAM and AVAC. We were joined by an expert panel discussing treatment as prevention, who took questions following their presentations. To view the full Flash animation of the webinar, click here.

  • March 15, 2013

    The Treatment Action Group (TAG) and AVAC recently released their latest report, Funding Scientific Innovation: Global Investments in HIV Treatment Research and Development in 2010 and 2011. The report, supported by UNAIDS, found US$2.6 billion was invested in HIV treatment research and development (R&D) in 2011.

  • March 11, 2013

    Results from the three-arm HIV prevention trial VOICE – Vaginal and Oral Interventions to Control the Epidemic – were recently presented at the 20th Conference on Retroviruses and Opportunistic Infections. The data showed that none of three interventions tested—daily oral tenofovir, daily oral TDF/FTC (Truvada), and daily 1% vaginal tenofovir gel—provided additional protection against HIV in this study, likely because few of the women in the trial used the products as directed.

  • March 3, 2013 to March 6, 2013

    The 20th Conference on Retroviruses and Opportunistic Infections (CROI) is a meeting of the world’s leading researchers working to understand, prevent, and treat HIV/AIDS and its complications. The goal of CROI is to provide a forum for translating laboratory and clinical research into progress against the AIDS epidemic.

  • February 26, 2013

    This 90-minute webinar examined the current state of research into topical microbicides – gels, lubes and devices that can be used to prevent HIV transmission during sex. It provided advocates with an overview of global and European topical microbicide research. The presentations were followed by a question and answer session with our expert speakers.